Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.